心脏肌钙蛋白I诊断急性心肌梗死的价值

目的 :探讨血清心脏肌钙蛋白 I（c Tn I）在急性心肌梗死 （AMI）中的诊断价值。方法 :急性心肌梗死 （AMI）组患者 2 0例 ,不稳定型心绞痛 （U A）组 31例 ,陈旧性心肌梗死 （OMI）组 11例 ,危重病患者 87例 （非心血管疾病 ）。AMI组患者系列采血测定血清 c Tn I和 CK- MB,U A与 OMI组、危重患者组均入院后次日晨取血 1次。结果 :c Tn I与CK- MB诊断 AMI的敏感性均为 10 0 % ,c Tn I诊断 AMI的特异性高于 CK- MB（P<0 .0 5 ） ;AMI时 c Tn I浓度高峰时间与 CK- MB平行 ,持续时间明显延长 （P<0 .0 1） ,溶栓患者高峰时间明显前移 （P<0 .0 1）。结论 :c Tn I诊断 AMI敏感性高 ,其特异性高于 CK- MB。且在血清中出现早且持续时间长。其峰值时间改变可用于判定 AMI的溶栓疗效     

冠状动脉支架置入术肌钙蛋白I的释放及相关临床因素

目的近年来研究表明心肌损伤检测生化标志物中肌钙蛋白 I(c Tn I)有较好的敏感性和特异性。本研究旨在探讨冠状动脉支架置入术 c Tn I的释放及相关临床因素。方法　 6 1例进行冠状动脉支架置入术的冠心病患者分别于术前、术后即刻、12小时、2 4小时检测磷酸肌酸激酶 (CK)、CK- MB、c Tn I,并采集临床、冠状动脉病变特征、手术过程、并发症等相关因素 ,并与 35例仅作冠状动脉造影的患者相比较。 CK>2 0 0 u/ l,CKMB>5 .6 ng/ m l,c Tn I>1.5 ng/ ml为心肌损伤临界值。结果　所有患者术前 c Tn I、CK、CK- MB均在正常范围。除 1例患者外其余患者均成功进行了支架置入术 ,无急诊冠状动脉搭桥术或死亡。术后 1例患者 CK升高 ,心电图证实为 Q波心肌梗死 ,其余患者 CK均在正常范围。成功进行支架置入术的 6 0例患者中术后 c Tn I及 CK- MB均升高 18例 ,c Tn I升高而 CK- MB正常 19例 ,CK- MB升高而 c Tn I正常 1例 ,CK- MB及 c Tn I均正常 2 2例。术后 c Tn I升高组同 c Tn I正常组比较 ,冠状动脉病变特征无显著性差异 ,术前冠状动脉内血栓形成及术中夹层、远端栓塞、急性闭塞并发症在 c Tn I升高组发生率相对较高 ,但无显著性差异。c Tn I及 CK - MB均升高组的术后 c Tn I、CK- MB水平较 c Tn I升高、CK- MB?     

cTnT在判断急性心肌梗死及不稳定型心绞痛预后中的价值

目的 :探讨心肌肌钙蛋白 T（c Tn T）对急性心肌梗死 （AMI）诊断及评估不稳定型心绞痛 （U AP）预后的临床价值。方法 :对 76例胸痛患者进行入院即刻血浆 c Tn T半定量、同步心肌酶学定量测定 ,观察对比 c Tn T与心肌酶学在诊断 AMI及评估 U AP患者预后中的特异性和敏感性。结果 :76例胸痛患者中 AMI 34例、U AP 2 7例、稳定劳力性心绞痛 8例、其它胸痛疾患 7例。AMI34例 c Tn T全部阳性 ,而 U AP2 3例和其余病例 c Tn T均为阴性。AMI患者同步 CK,AST升高者 2 8例 ,L DH升高者 30例。c Tn T与心肌酶学差异未达显著水平 （P>0 .0 5 ） ,但发病 2～ 5 h者 10例 ,心肌酶各项均正常 ,与 c Tn T对比有高度显著性差异 （P<0 .0 1） ;发病 5～ 11d者 6例 ,仅 2例 L DH还表现出升高外 ,其余心肌酶均正常 ,与 c Tn T对比有显著性差异 （P<0 .0 5 ） ;发病 5～ 12 0 h者相差均不显著 （P>0 .0 5 ）。在 2 7例 U AP患者中 ,c Tn T阳性组 AMI和难治性心绞痛发生率显著高于 c Tn T阴性组 （P<0 .0 1） ;c Tn T阴性组药物疗效好 ,近期心脏事件发生率低 ,与 c Tn T阳性组对比亦有高度显著性差异 （P<0 .0 1）。结论 :c Tn T是反映心肌细胞损伤灵敏性、特异性均较好的生化指标 ;c Tn T对诊断早期和晚期 AMI的价值高于心肌酶学 ;c Tn T阳性     

血清肌酸激酶同工酶升高的不稳定型心绞痛的临床特点

目的　探讨血清肌酸激酶同工酶 (CK- MB)升高的不稳定型心绞痛临床特点。方法　根据 CK活性正常但 CK-MB活性升高或正常将病人分为 CK- MB异常组 (n=42 )和正常组 (n=42 ) ,比较两组血清心肌肌钙蛋白 T(c Tn T)阳性发生率、左心室收缩功能、住院期间和一年内心肌梗死、心源性死亡发生率及一年内心绞痛复发率。结果　 CK- MB异常组中 CK - MB于症状出现 3～ 4h开始升高 ,12～ 17h达峰值 ,2 0～ 34 h回到正常 ;CK- MB异常组与 CK - MB正常组比较 ,c Tn T阳性率增加 (P<0 .0 1) ,左心室收缩功能差 ,住院期间和一年内心肌梗死、心源性死亡发生率及一年内心绞痛复发率均增高 (P<0 .0 5 )。结论　 CK- MB活性升高提示不稳定型心绞痛患者存在心肌损伤和具有较差的预后。     

C反应蛋白水平在冠心病中的意义

目的　探讨 C反应蛋白 (CRP)水平在冠心病中的变化及其预测预后的价值。方法　采用免疫透射比浊法测定 CPR水平 ,其中稳定型心绞痛组 38例 ,不稳定型心绞痛组 39例 ,急性心肌梗死组 2 9例和正常对照组 30例 ,采用交叉对照分析。结果　稳定型心绞痛组与正常对照组相比 ,CRP水平有所升高 ,但无统计学意义 (P>0 .0 5 ) ;不稳定型心绞痛组、急性心肌梗死组 CRP水平显著高于稳定型心绞痛组和正常对照组 (P<0 .0 1) ,且二者相比有差异性 (P<0 .0 5 )。 CRP>18m g/ L的患者 ,预后不良。结论　 CRP是冠心病形成的危险因子 ,并可作为冠心病患者判断预后的预测指标     

肌钙蛋白I和肌红蛋白在不稳定型心绞痛中的变化和近期预后判断

目的　对不稳定型心绞痛 ( UA)患者进行近期预后判断。方法　对 U A患者进行肌钙蛋白 I( c Tn I)和肌红蛋白 ( Mb)的定量测定并进行动态观察 ,同时进行心肌酶 CK-MB和 CK的对照试验。结果　根据 c Tn I峰值水平将 47例 UA患者分为 c Tn I正常组和升高组 ,两组间的一般临床特征除心绞痛分级以外 ,其余各项均无显著性差异 ( P>0 .0 5 ) ;c Tn I正常组和升高组之间 ,心脏事件的发生率为 4.2 %和 39.1% ,有显著性差异 ( P<0 .0 1) ;c Tn I低危水平和高危水平之间 ,心脏事件的发生率为 2 6.6%和 62 .5 % ,也有显著性差异 ( P<0 .0 5 ) ;c Tn I的动态演变与发生心脏事件密切相关 ( P<0 .0 5 ) ;在对 UA患者的预后判断中 ,c Tn I和 Mb的灵敏度为 90 %和 10 0 % ,阴性似然比为 0 .16和 0 ,表明 c Tn I和 Mb检测结果正常时发生心脏事件的可能性很小 ;在校正了 U A患者发生心脏事件的 2 0多个危险因子后 ,c Tn I的相对危险度优势比为 9.2 84,不仅是完全独立的危险因子 ,而且是因果相关性强度最大的危险因子。结论　c Tn I联合 Mb检测是评估 UA患者近期预后的良好指标 ,其灵敏度和特异性能得到最佳体现 ;c Tn I是独立的、因果相关性强度最大的危险因子     

经皮腔内冠状动脉成形术和支架术后心肌微损伤对近期临床预后的影响

目的 :通过观察血清肌钙蛋白I(cTnI)和肌酸激酶 同工酶 (CK MB)的变化 ,了解经皮腔内冠状动脉成形术 (PTCA)和支架术后心肌微损伤情况及其对近期预后的影响。方法 :选择 83例经造影证实为单支血管病变的稳定型心绞痛行PTCA和支架术后无严重并发症者。测定术前 ,术后 6、12、2 4及 4 8h血清cTnI、CK MB的水平 ,并随访观察术后 4～ 5周内心血管事件的发生情况 ,以及通过超声心动图检查术前和术后随访期间左室射血分数的变化。结果 :术后 2 3例出现cTnI或 (和 )CK MB阳性者 ,其中支架组 2 1例 ,球囊组 2例。cTnI阳性检出率 (2 4 .1% )明显高于CK MB阳性检出率 (6 .0 % ) (P <0 .0 1)。cTnI和 (或 )CK MB阳性 (损伤组 )术中球囊扩张的总时间、单次扩张最长时间以及分支血管阻塞的发生率均明显高于cTnI和 (或 )CK MB阴性 (未损伤组 ) (分别为P <0 .0 5、P <0 .0 1、P <0 .0 1) ,而球囊扩张次数和扩张的最大压力两组相比无明显差别 (P >0 .0 5 ) ,随访术后近期心血管事件的发生率和左室功能的变化两组无明显差异。结论 :PTCA及支架术后心肌微损伤并不少见 ,尤以支架术后发生率高。这种微损伤对近期预后的影响不大。检测这种微损伤的指标以cTnI明显优于CK MB。     

非体外循环冠状动脉旁路移植术围术期cTnI、CK及CK-MB的变化

目的 :通过对非体外循环冠状动脉旁路移植术 （OPCABG）患者 ,围手术期血清心肌肌钙蛋白 I（c Tn I）、肌酸磷酸激酶 （CK）、肌酸磷酸激酶同工酶 MB（CK- MB）变化的观察 ,探讨 OPCABG围手术期心肌损伤的情况。方法 :选择 2 0例全麻常温下进行 OPCABG患者及 2 0例同期行肺叶切除术患者 （对照组 ） ,麻醉诱导气管插管后以微量输液泵持续输注异丙酚、利多卡因复合液 ,并间断静脉注射芬太尼和哌库溴铵维持麻醉。在麻醉诱导前、术后 1h、2 4h、4 8h4个时间点抽取血样测定 c Tn I、CK、CK- MB值。结果 :所有患者手术经过及术后恢复顺利 ,OPCABG组无一例转为体外循环。两组患者术前 CK、CK- MB均在正常范围 ,术后 1h开始升高 ,术后 2 4 h达峰值 ,与麻醉前比较 ,均 P<0 .0 1;术后 4 8h明显下降 ,但仍高于麻醉前水平 （P<0 .0 1）。 4个时间点两组 CK、CK- MB值相比 ,差异无显著性。OPCABG组 c Tn I值与术前比较 ,术后 1h开始升高 （P<0 .0 1） ,2 4 h达峰值 （P<0 .0 1） ,术后 4 8h有所下降 ,但仍高于麻醉前水平 （P<0 .0 1） ;而肺叶切除组术后 c Tn I值始终不高。术前、术后 1h两组 c Tn I值差异无显著性 ,但 OPCABG组术后 2 4 h、4 8h值均明显高于肺叶切除组 （P<0 .0 1）。手术全程及术后 4 8h动态心电图未发现心肌梗死 ,血?     

心脏肌钙蛋白I对急性心肌梗死患者心功能预后的判断价值

目的 :探讨心脏肌钙蛋白 I（c Tn I）对急性心肌梗死 （AMI）患者心功能预后的判断价值。方法 :AMI患者 34例（溶栓再通组 18例 ,未溶栓组 16例 ） ,每例患者采用序列采血测定血清 c Tn I,并检测 1月末左心室射血分数（L VEF）。结果 :AMI患者血清的 ∑c Tn I与 1月末 L VEF呈负相关 （P<0 .0 5 ）。溶栓再通患者的 c Tn I峰值浓度与1月末 L VEF进行相关分析 ,有明显的负相关 （P<0 .0 5 ） ,未溶栓患者的 c Tn I峰值浓度与 1月末 L VEF无明显相关 （P>0 .0 5 ） ,溶栓再通患者 c Tn I峰值浓度明显高于未溶栓患者 （P<0 .0 1）。结论 :AMI患者的 ∑c Tn I和溶栓再通患者的峰值浓度均可作为判断左心功能的预后指标。     

C反应蛋白水平预测冠心病预后的意义

目的探讨C反应蛋白(CRP)水平在冠心病中的变化及其预测预后的价值。方法采用免疫透射比浊法测定CRP水平,其中稳定型心绞痛组34例,不稳定型心绞痛组36例,急性心肌梗死组26例和正常对照组32例,采用交叉对照分析。结果稳定型心绞痛组与正常对照组相比,CRP水平有所升高,但无统计学意义(P>0.05);不稳定型心绞痛组、急性心肌梗死组CRP水平显著高于稳定型心绞痛组和正常对照组(P<0.01),且二者相比有差异性(P<0.05)。CRP>18mg/L的患者,预后不良。结论CRP是冠心病的独立危险因素,并可作为患者判断预后的预测指标。     

Women react with more myocardial ischemia and angina pectoris during elective percutaneous transluminal coronary angioplasty

BACKGROUND: Women have been considered to be at higher risk of complications relating to percutaneous transluminal coronary angioplasty (PTCA) than are men. One reason for this sex-related difference could be the ischemic response of myocardium during the procedure. OBJECTIVE: To investigate whether there are sex-related differences in ischemic response of myocardium during elective PTCA. METHODS: Consecutive patients (n = 192, of whom 48 were women), were subjected to vectorcardiography during the PTCA procedure. Vectorcardiographic variables, magnitude of ST-segment vector (ST-VM), and magnitude of ST-segment vector change (STC-VM) were studied. RESULTS: Women were older (63 +/- 10 versus 56 +/- 10 years, P< 0.001) than men in our study and more often had diabetes mellitus and hypertension. Women less often had stents implanted (24 versus 50%, P < 0.01) and they were subjected to fewer balloon inflations (P < 0.001), with a total inflation time shorter than that for men (P< 0.001). Maximum STC-VM was 25% greater for women (P < 0.05). Women reported greater maximum pain (P < 0.05) and nitroglycerine was more frequently used for them during PTCA (P < 0.05). Occurrence of episodes of residual ischemic STC-VM (the difference between total number of episodes and number of balloon inflations) was more common for women (3 +/- 5 versus 1 +/- 3, P< 0.01). Duration of residual ischemic STC-VM episodes (the difference between total duration of episodes and duration of balloon inflations) was longer for women than it was for men (242 +/- 275 versus 148 +/- 233 s, P < 0.05). In a stepwise multivariate analysis and for a matched case-control group, episodes of residual STC-VM and duration of residual STC-VM episodes still indicated that there was an independent sex-related difference (P < 0.01 and P < 0.01, respectively). CONCLUSIONS: Women more commonly develop vectorcardiographic signs of severe myocardial ischemia, more frequently experience episodes of ischemia and report more severe angina pectoris during elective PTCA than do men.     

Comparison of results of intracoronary stenting in patients with unstable vs. stable angina

Percutaneous transluminal coronary angioplasty (PTCA) has higher complication and restenosis rates when performed in the setting of unstable angina. Balloon-expandable intracoronary stenting is a new technique with the potential to improve the results of PTCA. In order to determine whether stenting is associated with a poorer outcome in patients with unstable angina, we retrospectively examined our experience with the Palmaz-Schatz balloon-expandable intracoronary stent in 105 patients. Patients were divided into 2 groups on the basis of symptoms at the time of stent insertion: group I (n = 57) had stable angina pectoris, and group II (n = 48) had unstable angina defined as pain at rest despite antianginal therapy (Braunwald class II, III). Initial (30-d) and final (6-mo) success rates were defined as stent insertion without myocardial infarction, need for bypass surgery, death, and significant angina. Baseline characteristics were similar, although the patients with unstable symptoms were older, more likely to be female, and had a higher incidence of postinfarction angina. A total of 136 stents were successfully delivered to 97 target sites in 92% of patients. Major complications occurred in 4 patients (4%) and were due to subacute thrombosis in 3 of them. There were no differences in complication rates between patients receiving stents electively with stable vs. unstable symptoms (2% vs. 6%, p = NS). Six-mo. follow-up status was ascertained in 96% of patients and revealed overall clinical success in 83% with angiographic restenosis (≥ 50% stenosis) in 28% of patients. There were no significant differences between groups in rates of restenosis, follow-up angina class, or overall clinical success. Patients with unstable angina receiving intracoronary stents have similar complication, restenosis, and initial and final success rates as compared to stent placement in patients with stable symptoms. This finding differs from previous observations of conventional PTCA and may result from mechanical improvements in the vessel due to the stent (e.g., sealing intimal dissections) or the associated anticoagulation regimen.     

东菱克栓酶防治PTCA支架术后心绞痛的疗效

目的 :探讨东菱克栓酶防治经皮腔内冠状动脉成形术 （PTCA）支架术后心绞痛的临床疗效。方法 :32例 PT-CA及支架术后心绞痛患者在常规治疗基础上 ,分别于第 1,3,5天加用东菱克栓酶 15 ,10 ,10 BU ,检测其疗效及实验室指标。结果 :心绞痛的治疗有效率为 94 % ,心电图改善率为 71% ,硝酸甘油用量减少 5 0 %以上者占 94 %。治疗后纤维蛋白原、血细胞比容显著降低 （P<0 .0 1） ,而血小板计数、凝血酶原时间、活化的部分凝血活酶时间均无显著变化 （P>0 .0 5 ）。结论 :东菱克栓酶对 PTCA支架术后的心绞痛具有显著的治疗作用 ,出血、变态反应等不良反应少见     

经皮冠状动脉腔内成形术前后血清肌钙蛋白I的变化

目的：通过动态观察血清心肌肌钙蛋白Ｉ（ｃＴｎＩ）及肌酸激酶ＭＢ同工酶（ＣＫ－ＭＢ）的变化,以评价经皮冠状动脉腔内成形术对心肌的可能影响。方法：对５９例行经皮冠状动脉腔内成形术的冠心病患者,分别测定其术前,术后６、１２、２４、４８和７２小时的血清ｃＴｎＩ及ＣＫ－ＭＢ水平,并进行分组比较。结果：１８例患者术前血清ｃＴｎＩ正常,术后６小时升高,１２～２４小时达峰值,４８～７２小时渐降至正常;３１例患者术前、术后血清ｃＴｎＩ均正常;１０例患者术前、术后血清ｃＴｎＩ均高于正常值。全部病例中仅３例患者ＣＫ－ＭＢ增高。血清ｃＴｎＩ升高与球囊扩张总时间及扩张次数有关。结论：经皮冠状动脉腔内成形术可能会造成心肌微小损伤,ｃＴｎＩ为监测心肌损伤的可靠而灵敏指标。     

Coronary artery stenting in unstable angina pectoris: a comparison with stable angina pectoris

OBJECTIVE: To compare early complication rates in unselected cases of coronary artery stenting in patients with stable v unstable angina. SETTING: Tertiary referral centre. PATIENTS: 390 patients with stable angina pectoris (SAP) and 306 with unstable angina (UAP). Patients treated for acute myocardial infarction (primary angioplasty) or cardiogenic shock were excluded. INTERVENTIONS: 268 coronary stents were attempted in 211 patients (30.3%). Stents used included AVE (63%), Freedom (14%), NIR (7%), Palmaz-Schatz (5%), JO (5%), and Multilink (4%). Intravascular ultrasound was not used in any of the cases. All stented patients were treated with ticlopidine and aspirin together with periprocedural unfractionated heparin. RESULTS: 123 stents were successfully deployed in 99 SAP patients v 132 stents in 103 UAP patients. Failed deployment occurred with nine stents in SAP patients, v four in UAP patients (NS). Stent thrombosis occurred in four SAP patients and 11 UAP patients. Multivariate analysis showed no relation between stent thrombosis and clinical presentation (SAP v UAP), age, sex, target vessel, stent length, or make of stent. Stent thrombosis was associated with small vessel size (p < 0.001) and bailout stenting (p = 0.01) compared with elective stenting and stenting for suboptimal PTCA, with strong trends toward smaller stent diameter (p = 0.052) and number of stents deployed (p = 0.06). Most stent thromboses occurred in vessels < 3 mm diameter. CONCLUSIONS: Coronary artery stenting in unstable angina is safe in vessels >/= 3 mm diameter, with comparable initial success and stent thrombosis rates to stenting in stable angina.     

Short-, medium-, and long-term follow-up after percutaneous transluminal coronary angioplasty for stable and unstable angina pectoris

The first 840 consecutive patients who underwent percutaneous transluminal coronary angioplasty (PTCA) performed in the same institution were retrospectively assessed at an average follow-up period of 25 months after the initial procedure. The study population consisted of 506 patients with stable angina pectoris (group 1) and 334 patients with unstable angina pectoris (group 2). Clinical end points were death, nonfatal myocardial infarction, recurrent angina pectoris necessitating bypass surgery or repeat PTCA, and event-free survival. The two groups were comparable with respect to age, sex, previous myocardial infarction, ejection fraction, and number of diseased vessels. PTCA was successful in 83.0% of group 1 and 87.1% of group 2. Follow-up rates were expressed as events per attempted PTCA in a patient group. No difference in survival was observed between the two groups, the mortality rate being approximately 2.8% at 25 months. In the group with stable angina pectoris there was a lower incidence of nonfatal myocardial infarction within the first 24 hours after angioplasty; 4.3% vs 9.0% (p less than 0.01). During long-term follow-up the increase in the incidence of nonfatal myocardial infarction was similar, resulting in an overall long-term follow-up infarction rate of 8.3% and 14.2%, respectively (p less than 0.01). A higher event-free survival was observed in group 1 within 24 hours after PTCA: 93.7% vs 84.2% (p less than 0.01). During subsequent follow-up the difference in event-free survival between the two groups was no longer significant: 68.5% vs 61.2%.(ABSTRACT TRUNCATED AT 250 WORDS)     

Clinical one-year outcomes after stenting in acute myocardial infarction

We retrospectively review our results of 96 stent placements in 64 patients identified from our data base who received stents acutely and within 48 hr of acute myocardial infarction. The average age was 60 years; 77% were male. The average length of stay was 6.75 days. Three patients needed coronary artery bypass grafting (CABG) before discharge: 2 for stent occlusion and 1 for papillary muscle rupture. Need for CABG, further percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction, and death defined outcome. Mean patient follow-up was 10.3 (±5.3) months. Seventy-two percent of patients were free of outcome events at 1 year, 17% needed CABG, and 11% required further PTCA. There were 2 myocardial infarctions and 1 death. Presence of left bundle branch block on admission electrocardiogram and angina in hospital after stent placement predicted worse outcome (P < 0.01). Cathet. Cardiovasc. Diagn. 40:337–341, 1997. © 1997 Wiley-Liss, Inc.     

不稳定性心绞痛病人的介入治疗及随访

目的　观察 18例不稳定性心绞痛病人的经皮冠状动脉内成形术 (PTCA)后的即刻疗效及随访结果。方法　 18例不稳定心绞痛病人中 15例内科药物治疗平稳后二周行冠脉造影及PTCA ,3例因内科药物治疗效果不佳而行紧急的PTCA。成功 17例 ;病变共 33处 ,2 3处被治疗 ,置入支架 18支。结果　术后所有病人心绞痛症状缓解。术后随访平均 9个月 ,病人心功能 ,运动耐量 ,心律失常等均有明显改善。 14例病人心绞痛症状基本消失。 3例病人有心绞痛发作 ,但药物可以控制。 1例病人前降支完全闭塞导丝未能通过病变处而失败。 17例中无一例发生心肌梗塞或猝死。结论　不稳定心绞痛病人尽早进行冠脉造影及PTCA治疗是有必要的 ,成功率是高的     

心肌肌钙蛋白I在不稳定型心绞痛患者中的应用价值

目的：探讨心肌肌钙蛋白I（cTnl)检测在不稳定型绞痛患中的临床应用价值。方法：对80例不稳定型心绞痛（UAP）患进行临床Braunwald分级,固相层析免疫法测定血清cTnI,酶学法测定肌酸磷酸激酶（CK）及其同功酶（CK－MB）,并观察住院期间心脏事件发生率。结果：80例UAP患中22例（27．5％）血清cTnI检测呈弱阳性或阳性,而CK－MB仅2例（2．5％）升高（P＝0．0001）。cTnI阳性组（22例）与阴性组（58例）之间临床除Braunwald分级存在差异（77．3％比48．3％,P＝0．02）外,其他均无差异。住院期间发生心脏事件率在cTnI阳性组较阴性组明显增高（40．9％比6．9％,P＝0．007）,多元logistic回归分析发现,cTnI是预测不稳定型心绞痛患住院期间心脏事件的最主要独立危险因素。结论：心肌肌钙蛋白I是反映心肌细胞损伤较灵敏、较特异的指标,是判断不稳定型心绞痛患近期预后的最主要独立预测因素。     

不稳定型与稳定型心绞痛冠状动脉成形术的比较

目的　比较不稳定型心绞痛 (UA)与稳定型心绞痛 (SA)患者接受冠状动脉成形术 (PTCA)的疗效。方法　行PTCA的心绞痛患者 2 0 4例 ,分组比较UA与SA患者冠状动脉造影结果及PTCA术的近期和中期疗效。结果　①分组 :2 0 4例病人中 ,UA组 112例 (5 5 % ) ,SA组 92例 (45 % )。其中UA组心绞痛分级高于SA组 (P <0 0 5 )。②UA组复杂病变血管支数为 74(3 3 % ) ,SA组复杂病变血管 43支(2 0 % ) ,两组比较差异显著 (P <0 0 1) ;而SA组多支血管病变的发生较UA组为多 (P <0 0 5 )。③支架植入情况 :UA组有 114支血管共植入支架 143枚 ,占病变血管数的 5 1% ;SA组 5 4支血管共 67枚 ,占 2 5 % ,两组比较差异显著 (P <0 0 1) ,共 15 6例病人接受支架术。④术后 3 0d内无重大并发症发生 ,UA组复发胸痛较SA组高 (9%vs 3 % ,P <0 0 5 )。⑤随访 3～ 9个月 ,发生心肌梗死 3例 ,其中UA患者2例。复发胸痛两组分别为 12例和 16例 ,占 13 %和 14% ;临床再狭窄发生率分别为 2 0 %和 2 2 % ,均无显著差别。结论　PTCA/支架术对不稳定型与稳定型心绞痛患者的疗效相似 ,即刻成功率高 ,中期疗效满意